VLDL Is the Leading Actor in Lipid Abnormality in Patients With Diabetes and Obesity

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Endocrinology and Metabolism

• Publication date

  2017-09-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.14740/JEM.V7I4.432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data

  2016cited by this paper
• The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways.

  2012influential reference
• Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes

  2011cited by this paper
• Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.

  2001influential reference
• Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats.

  1995cited by this paper
• Postheparin Plasma Lipoprotein Lipase and Hepatic Lipase in Diabetes Mellitus: Relationship to Plasma Triglyceride Metabolism

  1977cited by this paper

• Sex Analysis of Lipid Profile in Diabetes Patients with and without Over Weight in Tikrit City/Iraq

  2022cites this paper
• Human Obesity and Diabetes, Is it Associated with COVID-19 Mortality

  2020cites this paper
• Obese Study , Keeping up Momentum

  2019cites this paper
• Diabetic dyslipidemia: evaluation and mechanism.

  2019cites this paper